Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3991 AL 4005

The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease

Broom GM, Shaw IC, Rucklidge JJ.

Nutrition. 2019 Apr;60:118-121. doi: 10.1016/j.nut.2018.10.003. Epub 2018 Oct 10.

Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis

Matsunaga S, Fujishiro H, Takechi H.

Int Psychogeriatr. 2019 Nov;31(11):1627-1633. doi: 10.1017/S1041610218002156. Epub 2018 Dec 18.

Biological clocks, some clock-related diseases, and medicinal plants

Deng TS.

Psych J. 2018 Dec;7(4):197-205. doi: 10.1002/pchj.263.

Atypical PKC: therapeutic target for Alzheimer's?

Farese RV, Sajan MP.

Aging (Albany NY). 2018 Dec 20;11(1):13-14. doi: 10.18632/aging.101730.

Liposome delivery systems for the treatment of Alzheimer's disease

Ross C, Taylor M, Fullwood N, Allsop D.

Int J Nanomedicine. 2018 Dec 12;13:8507-8522. doi: 10.2147/IJN.S183117. eCollection 2018.

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials

Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT.

Alzheimers Res Ther. 2018 Dec 27;10(1):126. doi: 10.1186/s13195-018-0457-9.

Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels

Fukunaga K, Izumi H, Yabuki Y, Shinoda Y, Shioda N, Han F.

J Pharmacol Sci. 2019 Feb;139(2):51-58. doi: 10.1016/j.jphs.2018.11.014. Epub 2018 Dec 18.

Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial

Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, Tajabadi-Ebrahimi M, Asemi Z.

Clin Nutr. 2019 Dec;38(6):2569-2575. doi: 10.1016/j.clnu.2018.11.034. Epub 2018 Dec 10.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R.

Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655.

CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease

Ambure P, Roy K.

Curr Drug Targets. 2017;18(5):522-533. doi: 10.2174/1389450116666150907104855.

Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease

Russo P, Kisialiou A, Moroni R, Prinzi G, Fini M.

Curr Drug Targets. 2017;18(10):1179-1190. doi: 10.2174/1389450116666151001111826.

Multi-Target Mining of Alzheimer Disease Proteome with Hansch's QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline

Abeijon P, Garcia-Mera X, Caamano O, Yanez M, Lopez-Castro E, Romero-Duran FJ, Gonzalez-Diaz H.

Curr Drug Targets. 2017;18(5):511-521. doi: 10.2174/1389450116666151102095243.

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE

Koster KP, Smith C, Valencia-Olvera AC, Thatcher GR, Tai LM, LaDu MJ.

Curr Top Med Chem. 2017;17(6):708-720. doi: 10.2174/1568026616666160617090227.

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease

Karl T, Garner B, Cheng D.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi: 10.1097/FBP.0000000000000247.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias